After receiving an investment of nearly 100 million yuan, Putian Bio’s business and strategic layout are expected to expand and increase the transformation and application of innovative technologies.
Recently, the A-round financing of Putian Biology officially landed, with CDH Baifu as the exclusive investment. After receiving an investment of nearly 100 million yuan, Putian Bio’s business and strategic layout are expected to expand and increase the transformation and application of innovative technologies.
Putian Bio is a national high-tech enterprise focusing on the cutting-edge multi-omics field of precision medicine, carrying out multi-omics research on genes + proteins + metabolism, and protein spectrum liquid biopsy technology with independent intellectual property rights. The core team comes from scientific research institutes such as Yale University, the National Institutes of Health, and the National Center for Protein Science. The company’s R&D pipeline covers early screening and diagnosis, recurrence monitoring, and companion diagnostic services for common cancers such as liver cancer, lung cancer, gastric cancer, esophageal cancer, colorectal cancer, and pancreatic cancer, pan-cancer types, and cardiovascular and cerebrovascular diseases. Umbrella with core intellectual property rights 
Clinical molecular database, clinical sample data 10W+, Putian is committed to continuous innovation of medical technology and its commercialization and clinical application.
Founded by Dr. Li Jie back in China in 2014, Putian has always focused on clinical needs, introduced proteomics and metabolomics on the basis of genomics, and brought systematic and comprehensive understanding research through “gene + protein + metabolism”, breaking the single genome It can bring more accurate and even individualized clinical solutions to clinical medicine. So far, Putian Biotech has carried out intellectual property layout in 7 templates including sample preparation, auxiliary materials, mass spectrometry detection, data analysis, and clinical application, and has the quality control ability of the whole process. Based on its rich technology and capacity reserves, Putian Biotech focuses on clinical needs, has accumulated a wealth of clinical sample cases, continuously develops innovative clinical solutions, and relies on medical laboratories to carry out clinical applications. At present, many products have entered the registration process. links.
Putian Biotech combines proteology and liquid biopsy to develop n-LAPE/MS with independent intellectual property rights This method has achieved a more than 10-fold increase in the identification of blood proteins. At present, Putian’s research and development pipeline has covered common cancers such as lung cancer and liver cancer, and preparations for certification have been started for many products. In the future, it will choose an opportunity to accelerate the investment process and strategic cooperation in this field.
Editor in charge: Wei Zirong
media reports
Entrepreneurship State Sina Technology Investment Circle
related events
- Putian Biotech completed the A-round financing of nearly 100 million yuan, CDH Baifu exclusive investment2023-01-28
- Dajian Biotech received 100 million yuan in Series A financing, led by Huada Winwin2020-03-27
- Tumor precision diagnosis company “Sidi” completed the first round of financing of 280 million yuan after the spin- off2020-01-06
- Tumor gene detection continues to be sought after by capital, “Shihe Gene” received 800 million yuan in round D financing2019-12-26
- Jiinga announced the completion of nearly 200 million yuan in Series B financing, BGI re – invested2019-09-30
This article is transferred from: https://readhub.cn/topic/8mWceb3stcs
This site is only for collection, and the copyright belongs to the original author.